948575-89-1Relevant academic research and scientific papers
Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations
Washburn,Harper,Wu,Godfrey,McCann,Girotra,Shao,Zhang,Gavai,Mikkilineni,Dejneka,Ahmed,Caringal,Hangeland,Zhang,Cheng,Russell,Skwish,Slusarchyk,Allen,Frohlich,Abboa-Offei,Cap,Waldron,George,Tesfamariam,Dickinson,Seymour,Sher
, p. 4290 - 4296 (2008/02/12)
Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective β3 agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent α1 adrenergic
